Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $607

Vertex Pharmaceuticals Incorporated -1.08%

Vertex Pharmaceuticals Incorporated

VRTX

439.46

-1.08%

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ: VRTX) with a Overweight and raises the price target from $606 to $607.